These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 20484426)

  • 1. 18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors.
    Troost EG; Bussink J; Hoffmann AL; Boerman OC; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 Jun; 51(6):866-74. PubMed ID: 20484426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 18F-FDG PET definition of gross tumor volume for radiotherapy of non-small cell lung cancer: is a single standardized uptake value threshold approach appropriate?
    Biehl KJ; Kong FM; Dehdashti F; Jin JY; Mutic S; El Naqa I; Siegel BA; Bradley JD
    J Nucl Med; 2006 Nov; 47(11):1808-12. PubMed ID: 17079814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of FDG PET/CT on delineation of the gross tumor volume for radiation planning in non-small-cell lung cancer.
    Spratt DE; Diaz R; McElmurray J; Csiki I; Duggan D; Lu B; Delbeke D
    Clin Nucl Med; 2010 Apr; 35(4):237-43. PubMed ID: 20305410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of interobserver reproducibility in quantitative 18F-FDG PET and CT measurements of tumor response to therapy.
    Jacene HA; Leboulleux S; Baba S; Chatzifotiadis D; Goudarzi B; Teytelbaum O; Horton KM; Kamel I; Macura KJ; Tsai HL; Kowalski J; Wahl RL
    J Nucl Med; 2009 Nov; 50(11):1760-9. PubMed ID: 19837757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET-CT-based auto-contouring in non-small-cell lung cancer correlates with pathology and reduces interobserver variability in the delineation of the primary tumor and involved nodal volumes.
    van Baardwijk A; Bosmans G; Boersma L; Buijsen J; Wanders S; Hochstenbag M; van Suylen RJ; Dekker A; Dehing-Oberije C; Houben R; Bentzen SM; van Kroonenburgh M; Lambin P; De Ruysscher D
    Int J Radiat Oncol Biol Phys; 2007 Jul; 68(3):771-8. PubMed ID: 17398018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity.
    Troost EG; Bussink J; Slootweg PJ; Peeters WJ; Merkx MA; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2010 May; 51(5):713-9. PubMed ID: 20395329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FDG-PET/CT imaging for staging and radiotherapy treatment planning of head and neck carcinoma.
    Deantonio L; Beldì D; Gambaro G; Loi G; Brambilla M; Inglese E; Krengli M
    Radiat Oncol; 2008 Sep; 3():29. PubMed ID: 18801181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients.
    Troost EG; Vogel WV; Merkx MA; Slootweg PJ; Marres HA; Peeters WJ; Bussink J; van der Kogel AJ; Oyen WJ; Kaanders JH
    J Nucl Med; 2007 May; 48(5):726-35. PubMed ID: 17475960
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment by a deformable registration method of the volumetric and positional changes of target volumes and organs at risk in pharyngo-laryngeal tumors treated with concomitant chemo-radiation.
    Castadot P; Geets X; Lee JA; Christian N; Grégoire V
    Radiother Oncol; 2010 May; 95(2):209-17. PubMed ID: 20385413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dose-escalation using intensity-modulated radiotherapy for prostate cancer--evaluation of the dose distribution with and without 18F-choline PET-CT detected simultaneous integrated boost.
    Pinkawa M; Attieh C; Piroth MD; Holy R; Nussen S; Klotz J; Hawickhorst R; Schäfer W; Eble MJ
    Radiother Oncol; 2009 Nov; 93(2):213-9. PubMed ID: 19717197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter clinical trial on the diagnostic value of dual-tracer PET/CT in pulmonary lesions using 3'-deoxy-3'-18F-fluorothymidine and 18F-FDG.
    Tian J; Yang X; Yu L; Chen P; Xin J; Ma L; Feng H; Tan Y; Zhao Z; Wu W
    J Nucl Med; 2008 Feb; 49(2):186-94. PubMed ID: 18199618
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Variation in radiotherapy target volume definition, dose to organs at risk and clinical target volumes using anatomic (computed tomography) versus combined anatomic and molecular imaging (positron emission tomography/computed tomography): intensity-modulated radiotherapy delivered using a tomotherapy Hi Art machine: final results of the VortigERN study.
    Chatterjee S; Frew J; Mott J; McCallum H; Stevenson P; Maxwell R; Wilsdon J; Kelly CG
    Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e173-9. PubMed ID: 23079100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients.
    Idema AJ; Hoffmann AL; Boogaarts HD; Troost EG; Wesseling P; Heerschap A; van der Graaf WT; Grotenhuis JA; Oyen WJ
    J Nucl Med; 2012 Dec; 53(12):1904-10. PubMed ID: 23077112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FLT PET/CT imaging is not competent for the pretreatment evaluation of metastatic gastric cancer: a comparison with 18F-FDG PET/CT imaging.
    Zhou M; Wang C; Hu S; Zhang Y; Yao Z; Li J; Guo W; Zhang Y
    Nucl Med Commun; 2013 Jul; 34(7):694-700. PubMed ID: 23604223
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gradient-based delineation of the primary GTV on FLT PET in squamous cell cancer of the thoracic esophagus and impact on radiotherapy planning.
    Zhang G; Han D; Ma C; Lu J; Sun T; Liu T; Zhu J; Zhou J; Yin Y
    Radiat Oncol; 2015 Jan; 10():11. PubMed ID: 25572431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictive value of 3'-deoxy-3'-[18F]fluorothymidine positron emission tomography/computed tomography for outcome of carbon ion radiotherapy in patients with head and neck mucosal malignant melanoma.
    Inubushi M; Saga T; Koizumi M; Takagi R; Hasegawa A; Koto M; Wakatuki M; Morikawa T; Yoshikawa K; Tanimoto K; Fukumura T; Yamada S; Kamada T
    Ann Nucl Med; 2013 Jan; 27(1):1-10. PubMed ID: 22914968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PET/CT with 18F-FLT: does it improve the therapeutic management of metastatic germ cell tumors?
    Pfannenberg C; Aschoff P; Dittmann H; Mayer F; Reischl G; von Weyhern C; Kanz L; Claussen CD; Bares R; Hartmann JT
    J Nucl Med; 2010 Jun; 51(6):845-53. PubMed ID: 20484416
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous positron emission tomography (PET) assessment of metabolism with ¹⁸F-fluoro-2-deoxy-d-glucose (FDG), proliferation with ¹⁸F-fluoro-thymidine (FLT), and hypoxia with ¹⁸fluoro-misonidazole (F-miso) before and during radiotherapy in patients with non-small-cell lung cancer (NSCLC): a pilot study.
    Vera P; Bohn P; Edet-Sanson A; Salles A; Hapdey S; Gardin I; Ménard JF; Modzelewski R; Thiberville L; Dubray B
    Radiother Oncol; 2011 Jan; 98(1):109-16. PubMed ID: 21056487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Variation in background intensity affects PET-based gross tumor volume delineation in non-small-cell lung cancer: the need for individualized information.
    Chen GH; Yao ZF; Fan XW; Zhang YJ; Gao HQ; Qian W; Wu KL; Jiang GL
    Radiother Oncol; 2013 Oct; 109(1):71-6. PubMed ID: 24060171
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.